Validation of hyperpolarised [1,4-
13C2] fumarate as a candidate for prognostic and treatment response marker for RENAL cancer
Professor Evis Sala, University of Cambridge
We have shown in preclinical studies that hyperpolarised [1,4-
13C2] fumarate magnetic resonance imaging can be used as an imaging biomarker to assess tumor necrosis as well as tubular necrosis in the kidney.
The hyperpolarised MRI agent [1,4-
13C2] fumarate is currently undergoing the required preclinical safety and toxicology studies, in preparation for a first-in-man clinical trial, led by Dr Ferdia Gallagher.
The clinical study will be conducted at 2 centres, the University of Cambridge and UCL, to evaluate hyperpolarised [1,4-
13C2] fumarate in renal cancer patients scheduled for nephrectomy.
13C magnetic resonance spectroscopic imaging (
13C MRSI) measurements of tumour malate production as a marker of tumour cell death will be undertaken prior to surgery. Cell death will also be assessed using diffusion weighted MRI and histological examination and the results compared to those obtained using hyperpolarised [1,4-
13C2] fumarate MRI.
This study will provide the data required to apply for further funding to perform a multi-centre clinical evaluation study in renal cancer patients using hyperpolarised [1,4- 13C2] fumarate MRI.